EU/3/15/1607: Orphan designation for the treatment of acute radiation syndrome
Entolimod
Table of contents
Overview
Please note that this product was withdrawn from the Union Register of orphan medicinal products in May 2020 on request of the Sponsor.
On 11 January 2016, orphan designation (EU/3/15/1607) was granted by the European Commission to TMC Pharma Services Ltd, United Kingdom, for entolimod for the treatment of acute radiation syndrome.
The sponsorship was transferred to TMC Pharma (EU) Limited, Ireland, in February 2019.
Key facts
Active substance |
Entolimod
|
Intended use |
Treatment of acute radiation syndrome
|
Orphan designation status |
Withdrawn
|
EU designation number |
EU/3/15/1607
|
Date of designation |
11/01/2016
|
Sponsor |
TMC Pharma (EU) Limited |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: